EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 2, 2012, Pages 245-249

  Gorden, Kimberly J ^a   Mesbah, Parvin ^a   Kolesar, Jill M ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

erlotinib; gefitinib; Nonsmall cell lung cancer

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL;

ALOPECIA; ANEMIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; EXON; GENE DOSAGE; GENE MUTATION; HAIR GROWTH; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; INTERSTITIAL LUNG DISEASE; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; XEROSIS;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84871768537     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211408373     Document Type: Review

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 ; 60 (5). 277-300
2. National Cancer Institute: U.S. National Institutes of Health. 'What you Need to Know About Lung Cancer', http://www.cancer.gov/cancertopics/wyntk/lung (accessed January 2010).
3. NCCN. National Comprehensive Cancer Network clinical practice guidelines in oncology: non-small cell lung cancer, Version 2.2010, 2010
4. Mok TS, WU Y, Thongprasert S, et al. Gefitinib or caboplatin-paclitaxel in pulmonary adenocarcinoma. NEngl J Med. 2009 ; 361 (10). 947-957
5. Wang Y, Minoshima S, Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. J Hum Genet. 1993 ; 38 (4). 399-406
6. Sharma S, Bell D, Settleman J, Haber D. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer. 2007 ; 7 (3). 169-181
7. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 ; 361 (10). 958-967
8. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 ; 27 (9). 1394-1400
9. Shepherd F, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 ; 353 (2). 123-132
10. Tsao M, Sakurada A, Cutz J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. NEngl J Med. 2005 ; 353 (2). 133-144
11. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 ; 11 (6). 521-529
12. Rosell R, Moran T, Queralt C, et al. Spanish lung cancer group, screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 ; 361 (10). 958-967
13. Maemondo M, Inoue A, Kobayashi K, et al. North-east Japan study group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 ; 362 (25). 2380-2388
14. Azzoli C, Baker S, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009 ; 27 (36). 6251-6266
15. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer. 2009 ; 10 (2). 106-111
16. Lynch TJ, Kim ES, Eaby B, Garey J, West D, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007 ; 12 (5). 610-621
17. Thatcher N, Nicolson M, Groves R, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K. Oncologist. 2009 ; 14 (8). 840-847
18. Jia Y, Lacouture ME, Su X, Wu S. Risk of skin rash associated with Erlotinib in cancer patients: a meta-analysis. J Support Oncol. 2009 ; 7 (6). 211-217
19. Hotta K, Kiura K, Takigawa N, et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2010 ; 5 (2). 179-184
20. Rakhit A, Pantze M, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol. 2008 ; 64 (1). 31-41
21. Ling J, Fettner S, Lum B, Riek M, Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008 ; 19 (2). 209-216
22. Tarceva (erlotinib). Melville, NY: OSI Pharmaceuticals, Inc. ; 2008.